The significance of tumor cell contamination in marrow and peripheral blood stem cell (PBSC) collections of patients with solid tumors remains controversial. Various methods have been developed to purge tumor cells from autologous stem cell products, including CD34 þ selection. PBSC harvests from patients with Ewing family of tumors (EFT) were analyzed for contaminating tumor cells prior and after CD34 þ selection using reverse transcriptionpolymerase chain reaction (RT-PCR) and flow cytometry (FC) analyzes. The expression of CD34 was studied by RT-PCR and FC in 14 primary tumors and 13 PBSC harvests, respectively. Tumor cells were identified in the harvests by both methods. In two patients, contaminating tumor cells were evident by RT-PCR only after positive selection. FC analysis confirmed a higher level of tumor cells in the CD34 þ fraction. In an attempt to explore this finding, expression of CD34 was detected in 93% of primary tumors and 67% of contaminated harvests. As CD34 is expressed on EFT cells, these cells may be enriched following CD34 þ selection of harvests, although the total number of tumor cells is reduced. Other methods of purging, rather than CD34 þ selection, should be explored in patients with EFT undergoing autologous stem cell transplantation.
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Introduction
A major cause of treatment failure in patients undergoing stem cell transplantation for malignancies is disease recurrence. Contaminated stem cell harvests have been suggested as one of the possible causes leading to relapse. Many studies have reported tumor cells to be present in bone marrow harvests and mobilized peripheral blood stem cell (PBSC) collections from patients with various malignancies. The significance of tumor cell contamination of autografts remains controversial, even though a shorter progression free survival has been shown for a number of malignancies. 1 Methods have been developed to purge tumor cells from autologous stem cell products. One method is the positive selection of CD34-expressing cells. 2 In allogeneic transplantation, a 3-5 log reduction of T cells can be obtained by CD34 þ selection to reduce the incidence and severity of graft-versus-host disease. Following this experience, clinical studies have demonstrated that a 2-5 log reduction of contaminating cells could be achieved in the autologous setting by CD34 þ selection. Transplantation with positively selected autologous CD34
þ PBSC results in a rapid and stable neutrophil and platelet engraftment. 2 Voso et al. 3 have concluded that immunomagnetic selection of CD34 þ cells provides autografts with reduced tumor cells and an engraftment ability similar to that of unmanipulated autografts, based on 29, 39 and 34 patients with non-Hodgkin's lymphoma, multiple myeloma and breast cancer, respectively. However, progression free survival of high-risk breast cancer patients was identical in both purged and unpurged arms in a prospective randomized study. 4 The effect of CD34 þ selection on the amount of contaminating cells was tested in neuroblastoma and multiple myeloma patients. [5] [6] [7] [8] Fifty-six percent (9/16) of PBSC collections remained polymerase chain reaction (PCR) positive for the expression of tyrosine hydroxylase in stage 4 neuroblastoma patients after positive selection with anti-CD34, but the absolute number of re-infused tumor cells was decreased. 6 Even though there was a depletion of the tumor cell load by a median of 3.1 log in a selected PBSC group of multiple myeloma patients, there was no difference in response rate and progression-free survival between the two arms that received CD34 þ selected or unselected PBSC products. 7, 8 Ewing Sarcoma (ES) is the second most common primary malignant bone tumor in children and adolescents, and it belongs to a group of neuroectodermal tumors known as ES family of tumors (EFT). 9 All EFT share one of the following specific translocations t(11;22), t(21;22), t(7;22), t(17;22) and t(2;22). [10] [11] [12] [13] [14] These translocations result in the fusion of the EWS gene on 22q12 with different ETS transcription family genes, FLI-1 (85-90%), ERG (5-10%), ETV-1, E1AF (1%) and rarely FEV. The various EWS rearrangements appear to be pivotal events in EFT tumorigenesis and these genetic alterations are considered distinct diagnostic features of these tumors. 19 We and others have previously studied tumor contamination in PBSC harvests from EFT patients and revealed a high incidence of contamination. [15] [16] [17] [18] [19] Toretsky et al.
15
identified the chimeric transcript in the blood progenitor cell collections of all five of their EFT patients studied. Leung et al. 16 studied five high-risk EFT patients and all were reverse transcription (RT)-PCR positive, either in marrow or blood grafts. At least one positive collection was identified in one out of nine and 10 out of 15 high-risk EFT patients. 17, 18 In our previous study, tumor-contaminated harvests were detected by RT-PCR in all 11 patients in at least one of the collections. 19 In this study, we investigated tumor cell contamination in harvests from EFT patients prior and after CD34 þ selection by RT-PCR and flow cytometry (FC) analyses and studied primary tumor cells for mRNA expression of CD34 by RT-PCR.
Materials and methods

Patients
Samples (tumors and/or harvests) were obtained from 26 patients diagnosed with EFT and treated in the Pediatric Hematology Oncology Department at Schneider Children's Medical Center of Israel. Informed consent was obtained from the patients or their guardians, and the local and national ethics committees approved the research project. The diagnosis was confirmed by pathology, immunohistochemistry and molecular analysis and all tumors harbored the EWS-FLI-1 chimeric transcript. Metastatic disease at diagnosis was present in five patients and 18 had progressed. In seven patients, the pelvis was the primary site. Forty-three percent (9/21) of the patients were poor responders, defined as o90% necrosis at definitive surgery. Indications for autologous transplant were: primary metastatic disease, poor response, primary site that could not be surgically removed with tumor free margins and chemosensitive relapse. CD34
þ selection was performed on harvests from four patients (no. 1-4 in all tables). At the time of harvest, two patients were in partial response and two in complete remission.
Treatment
Primary treatment consisted of chemotherapy according to the VACA or IV-VACA protocols (vincristine, actinomycin-D, cyclophosphamide, adriamycin, ifosfamide, etoposide), surgery and radiotherapy. When complete remission or very good partial remission was achieved, patients underwent stem cell collection after G-CSF mobilization, followed by conditioning with melphalan etoposide and carboplatin or busulfan and melphalan, and autologous stem-cell reinfusion.
CD34
þ selection Leukapheresis was performed on a continuous-flow blood cell separator (Cobe Spectra, Lakewood, CO, USA). CD34
þ selection was performed using the CliniMACS device (Miltenyi Biotech, Bergisch Gladbach, Germany) according to the manufacturer's instructions. 20 After appropriate cell labeling and washes, a sample of 200 ml was taken for cell count, CD34 determination and RT-PCR analysis of the chimeric transcript. The cell bag was attached to a micro-aggregate filter and loaded onto the high-gradient magnetic separation cliniMACS column. 
RT-PCR
Total RNA was isolated from the biopsies or harvests with the TRI-reagent (MRC, Cincinnati, OH, USA). RT-PCR was performed with the Access RT-PCR System (Promega, Madison, WI, USA) according to instructions with 1 mg total RNA, 2.5 mM magnesium, random hexamers and previously described primers 22.8 þ 22.4 10, 21 for the normal EWS gene and 22.8 with Fli 11 22 for the EWS-FLI-1 fusion transcript. Nested PCR was performed with primers 22.3 with Fli 3 22 after the cDNA was diluted 1:50. Annealing and extension temperatures were, respectively, 69 and 721C for the FLI-1 transcript. For the CD34 expression, primers described by Hafer et al. 23 were used with annealing and extension temperatures of 68 and 721C, respectively. The quality of the RNA was tested in an additional RT-PCR analysis of the ATM gene (data not shown).
FC analysis Samples from harvests and CD34
þ and CD34 À fractions were incubated with a combination of four color antibodies: CD99 fluorescein isothiocyanate clone TU12, CD45 PerCP clone HI30, (BD Pharmingen, San Diego, CA, USA) and CD117 PE clone MIB-1 (Dako, Carpinteria, CA, USA). 24 Samples were analyzed by FACS Calibur flow cytometer using the CellQuest-Pro software for acquisition and analysis (Becton Dickinson Immunocytometry Systems, BD Biosciences, San Jose, CA, USA). Isotype matched control monoclonal antibodies were used to determine nonspecific binding. A total of 300 000 events
per sample tube were collected achieving a sensitivity of one tumor cell in 10 000 nucleated cells. Additional 13 harvests were analyzed simultaneously for contamination of Ewing cells and for CD34 expression using CD34 PerCP clone 8G12 (Becton Dickinson Immunocytometry Systems). Analysis was performed on live cells (to prevent false positivity or negativity), but the final results were the percent of positive cells in total acquired events.
Results
Identification of
þ fractions were RT-PCR positive. Based on these results, contaminating tumor cells are present after CD34 þ selection. Furthermore, the non-selected harvests from the two patients that were RT-PCR negative became RT-PCR positive following the positive selection procedure in the CD34 þ fraction (Figure 1 ). In order to validate these results, the available PBSC harvests from patients no 1 to 3, prior and after CD34 
À (results summarized in Table 1 and Figure 2 ). In both, EFT cells could be identified in the harvest before CD34 þ selection and in both the negative and positive fractions. The percentage of EFT cells was increased after the CD34 þ selection patient in no. 1 from 0.11 to 0.95 and in patient no. 3 from 0.03 to 2.01, even though total tumor cell numbers were reduced by the selection process by about 75%. These results support the results obtained by RT-PCR for the chimeric transcript.
CD34 expression in ES primary tumors and harvests Based on our results of identification of EFT cells in the CD34
þ fraction, we wished to evaluate whether EFT cells express CD34 using two methods, as follows: RT-PCR of 14 tumors was conducted to assess RNA level and FC analysis of 13 additional harvest samples (as no fresh viable tumors were available) to evaluate the protein level.
CD34 expression was detected in 13 out of 14 tumors (93%) at diagnosis using RT-PCR (Figure 3) .
The FC analysis was performed in two stages. EFT cells were first identified and then these cells were assessed for CD34 expression on the cell surface. The results are summarized in Table 2 . Twelve out of the 13 (92%) harvests were contaminated with EFT cells in percentages ranging from 0.02 to 0.51. CD34 expression was evident in eight out of these 12 (67%) harvests, ranging from 8 to 97 percent. There was no correlation between the amount of CD34 expression and amount of EFT cells (Table 2 ). 
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Clinical correlation with CD34 expression CD34 expression was evaluated in 14 tumors and 13 harvests. In one patient, both the tumor and harvest samples were analyzed (no. 14 and 22 in Table 3 , respectively). Tumor cells were not evident in the harvest, and CD34 could not be detected. Altogether, the majority of samples (21 out of 26; 81%) expressed CD34. No association could be identified between CD34 expression and clinical features; age (defined as higher or lower than 12 years), primary site (pelvis vs other) and percentage of necrosis (above and below 90%). þ selection (with an observed reduction in tumor load of 2-4 logs) in harvests from neuroblastoma patients and they too have shown one sample that was RT-PCR negative before selection and turned to be positive after selection, indicating an increase in the amount of the contaminating tumor cells.
These observations raise the question whether tumor cells also express the CD34 antigen on their surface and thus are captured and enriched for, following the CD34 selection process. This issue was addressed in various tumors, confirming the expression of CD34 in solid tumors. 23, [26] [27] [28] Expression of CD34 was confirmed by several methods: FC analysis, Western blotting and mRNA level in neuroblastoma cell lines. 23, 26 Eight out of 16 cell lines had a positive CD34 mRNA expression, and all but one cell line were positive for at least one clone for more than 20% of cultured cells with a panel of five different anti-CD34 antibody clones. 23, 26 Expression of CD34 was analyzed by immunohistochemistry on 11 formalin-fixed paraffin-embedded malignant peripheral nerve sheath tumors, and in two of them CD34 was positive. 27 Two small cell lung cancer cell lines were found to be positive for CD34 analyzed by FC and expression was confirmed by RT-PCR. 28 This suggests that caution should be taken using PBSC positively selected for CD34 þ from patients with these solid tumors. 23, [26] [27] [28] We addressed this issue in ES primary tumor cells and have identified CD34 mRNA expression in 13 out of 14 tumors tested (93%). CD34 protein expression was evident by FC analysis in 67% of harvests. In view of these findings, we also suggest that tumor cells should be tested for CD34 expression before considering CD34 þ selection of harvests in patients with EFT. Another validation of the results demonstrated in this study, came from our gene expression profiling study in ES using Affymetrix oligonucleotide U95Av2. CD34 (accession number M81945) was expressed in 14 primary tumors and six metastases obtained from 18 EFT patients. 29 We could not detect any correlation between CD34 expression and the known clinical prognostic parameters in EFT.
As CD34 þ selection does not reach a level of even 1 log depletion of tumor cells in patients with ES-expressing CD34, if purging is to be performed an alternative method should be used, for example, by using the monoclonal antibody 8H9 as demonstrated by Merino et al. 30 This antibody binds to ES cells and not to normal hematopoietic cells, and they showed a 2-3 log reduction in contaminating cells. Another possibility is to add a negative selection step following positive selection. A high purging efficacy of more than five logs was achieved by combination of both positive (by CD34 þ ) and negative (by anti CD19/20/23/37) selection in B-cell chronic lymphocytic leukemia and B-cell non-Hodgkin's lymphoma. 31, 32 In conclusion, we have demonstrated the expression of CD34 in ES tumor cells and the possible increase in percentage of these cells following CD34 þ selection of PBSC harvests, although total number of contaminating cells is reduced to a certain extent. Owing to these findings, the clinical relevance of alternative purging methods of PBSC harvest of patients with EFT should be explored.
